Sign in
Active, not recruitingPhase 2

Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia

Key facts

Who runs it
Ohio State University
Where
Boca Raton, Columbus, Indianapolis, Lowell, Maywood, and Miami, United StatesSee the 6 sitesAlso in 1 other country, 1 site
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
37 people enrolled
Started
28 Aug 2020
Expected to end
31 Dec 2026
Type of study
Interventional, 3 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Low dose radiation 35 cGy
  • High dose radiation 100 cGy
Record updated
16 April 2026

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Laboratory-confirmed diagnosis of SARS-CoV-2 pneumonia
  • Currently hospitalized with COVID-19
  • Symptomatic fever, cough and/or dyspnea for < 9 days
  • Patient or legal/authorized representative can understand and sign the study informed consent document
  • Able to be positioned on a linear-accelerator couch for Radiation Therapy delivery
  • And at least one of the following risk factors for significant pulmonary compromise:; Fever > 102 degrees Fahrenheit during index admission; Respiratory rate of ≥ 26 / minute within 24 hours of screening; SpO2 ≤ 95% on room air within 24 hours of screening; Any patient requiring 4 L/min oxygen therapy to maintain SpO2 >93% within 24 hours of screening; Ratio of partial pressure of arterial oxygen to fraction of inspired air < 320
  • Patients may be enrolled on this trial while concurrently enrolled on other COVID-19 clinical trials

Who cannot take part

  • Prior thoracic radiotherapy, with the exception of the following:; Breast or post-mastectomy chest wall radiation (without regional nodal irradiation) may be included at the discretion of the site primary investigator, and; Thoracic skin radiation therapy (without regional nodal irradiation) is allowed
  • Known prior systemic use of the following drugs: Bleomycin, Carmustine, Methotrexate, Busulfan, Cyclophosphamide, or Amiodarone
  • History of recent or current malignancy receiving any cytotoxic chemotherapy or immunotherapy within the past 6 months
  • Inability to undergo radiotherapy for any other medical or cognitive issues
  • Known hereditary syndrome with increased sensitivity to radiotherapy, including ataxia-telangiectasia, xeroderma pigmentosum, and Nijmegen Breakage Syndrome
  • History of or current diagnosis of pulmonary fibrosis, or an alternative pulmonary condition responsible for significant lung compromise at the discretion of the site primary investigator
  • History of lung lobectomy or pneumonectomy
  • Known history of pulmonary sarcoidosis, Wegener's granulomatosis, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, polymyositis/dermatomyositis, Sjögren's syndrome, mixed connective tissue disease, Churg-Strauss syndrome, Goodpasture's syndrome, or ankylosing spondylitis
  • Symptomatic congestive heart failure within the past 6 months including during current hospitalization
  • History of bone marrow transplantation
  • History of any solid organ transplant (renal, cardiac, liver, lung) requiring immunosuppressive therapy
  • Currently requiring mechanical ventilation
  • Females who are pregnant or breast feeding

Where in United States

Also in 1 other country, 1 site

  • Boca Raton Regional Hospital -Lynn Cancer InstituteBoca Raton, United States
  • Ohio State University James Cancer HospitalColumbus, United States
  • Indiana University School of MedicineIndianapolis, United States
  • Lowell General Hospital Cancer CenterLowell, United States
  • Loyola University ChicagoMaywood, United States
  • Miami Cancer InstituteMiami, United States

About the trial

What the trial wants to find out

Low doses of radiation in the form of chest x-rays has been in the past to treat people with pneumonia. This treatment was thought to reduce inflammation and was found to be effective without side effects. However, it was an expensive treatment and was eventually replaced with less expensive treatment options like penicillin.

Read full original descriptionShow less

The COVID-19 virus has emerged recently, causing high rates of pneumonia in people. The authors believe that giving a small dose of radiation to the lungs may reduce inflammation and neutralize the pneumonia caused by COVID-19. For this study, the x-ray given is called radiation therapy. Radiation therapy uses high-energy X-ray beams from a large machine to target the lungs and reduce inflammation. Usually, it is given at much higher doses to treat cancers.

The purpose of this study is to find out if adding a single treatment of low-dose x-rays to the lungs might reduce the amount of inflammation in the lungs from COVID-19 infection, which could reduce the need for a ventilator or breathing tube.

The 3 groups in the trial

  • Low radiation armTreatment being tested

    A single dose of 35 cGY delivered to the whole thorax

    Treatment: Low dose radiation 35 cGy

  • High radiation armTreatment being tested

    A single dose of 100 cGY delivered to the whole thorax

    Treatment: High dose radiation 100 cGy

  • Control armNo study treatment, for comparison

    Patients will receive no radiation therapy but will have research samples collected and best supportive care

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase II Protocol of Low-Dose Whole Thorax Megavoltage Radiotherapy for Patients With SARS-COV-2 Pneumonia
Publications
Record updated
16 April 2026